Pfizer Inc
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
Exterior view of the entrance to Merck headquarters on February 05, 2024 in Rahway, New Jersey. Spencer Platt | Getty Images Merck on Thursday reported first-quarter revenue and adjusted earnings that topped expectations as it posted strong sales of its blockbuster cancer drug Keytruda and vaccine products. The pharmaceutical giant also raised and narrowed its […]
Read More
Biotech stocks are ready to break out. They just need one more thing
While debate rages on about when the Federal Reserve might start cutting interest rates, biotech industry analysts are making the case that the argument for stocks in the sector is growing. The central bank has held rates steady since last July as it patiently waits for more signs that inflation is cooling. But a reading […]
Read More
Stocks making the greatest moves midday: Boeing, Norfolk Southern, Nvidia & more
Check out out the corporations earning headlines in midday investing. BlackBerry — BlackBerry shares popped more than 9% immediately after the business announced a partnership with Sophisticated Micro Equipment on robotics programs. Moderna — The vaccine maker received 6%. Reuters claimed that Moderna’s most cancers drug it is performing on with Merck confirmed promising results […]
Read More
Shares producing the biggest moves premarket: American Eagle Outfitters, Ally Monetary, Molson Coors Beverage and much more
Check out out the companies generating headlines prior to the bell: American Eagle Outfitters — Shares popped 4% subsequent an enhance by JPMorgan to chubby from neutral. The firm cited the retailer’s merchandising initiatives and operational adjustments for the simply call. Freeport-McMoRan — Shares jumped 1.9% immediately after Financial institution of The united states upgraded […]
Read More
Pfizer’s RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use
Respiratory syncytial virus – viral vaccine under research Hailshadow | Istock | Getty Images A vaccine from Pfizer showed the potential to protect adults ages 18 to 59 who are at increased risk of getting severely sick from respiratory syncytial virus in a late stage clinical trial, the company said Tuesday. The initial data suggests […]
Read More
Moderna says new Covid vaccine showed stronger immune response than current shot in study
A nurse fills a syringe with Moderna Covid-19 vaccine. Fred Tanneau | Afp | Getty Images Moderna on Tuesday said a new version of its Covid vaccine triggered a stronger immune response against the virus than its current shot in a late-stage trial. The results come as Moderna competes with rival Pfizer for more share […]
Read More
This forgotten corner of women's health could be a $350 billion sector possibility
Peathegee Inc | Tetra Visuals | Getty Visuals Following decades of becoming overlooked, menopause has entered the community dialogue. Famous people from Drew Barrymore to Naomi Watts have opened up about symptoms and promoted goods. Nonetheless even with the amplified chatter, there is a extended way to go when it comes to treating indicators — […]
Read More
CNBC Day-to-day Open: A blended image on U.S. employment development
Employees at a cafe at Grand Central Market place in Los Angeles, California, US, on Thursday, Nov. 2, 2023. Eric Thayer | Bloomberg | Getty Images This report is from modern CNBC Everyday Open up, our international markets e-newsletter. CNBC Day-to-day Open up brings buyers up to pace on anything they want to know, no […]
Read More
Pfizer is betting big on cancer drugs to turn business around after Covid decline – here's what to know
Nurphoto | Nurphoto | Getty Images Pfizer is ready to move on from Covid. Now, the company is betting on cancer drugs to help it regain its footing after a rocky year marked by the rapid decline of its Covid business. It just might take a while before that bet pays off. Pfizer pitched its […]
Read More
Pfizer RSV vaccine maintains protection in older adults over two seasons in trial
Respiratory syncytial virus vial. Manjurul | Istock | Getty Images Pfizer‘s vaccine against respiratory syncytial virus maintained protection for older adults across two full seasons of the disease in an ongoing late-stage clinical trial, the company announced Thursday. The shot’s efficacy declined slightly compared with the levels of protection after one RSV season, but the […]
Read More